Market Signal Briefing

Highlights

Amended Arrangement Agreement: Robex and Predictive Discovery have agreed to revised terms under the amended arrangement agreement. Robex Shareholders will receive 7.862 Predictive Shares for each Robex Share, resulting in Robex Shareholders owning 46.5% of the combined company on a fully diluted in-the-money basis.Strong Shareholder Support: Shareholders have expressed strong support for the transaction, with major shareholders, directors and officers of Robex (representing ~23.8% of the outstanding Robex Shares) entering into separate amended voting agreements.Strategic Benefits: The merger creates one of West Africa’s leading gold producers, combining two large, low-cost, and advanced projects with significant growth potential.Accretive Value: The transaction is expected to be accretive to shareholders of the combined company over the medium term, supported by attractive exposure to the merged group’s high-quality assets, increased scale, increased asset diversification, and potential index inclusion.Meeting Update: The deadline for Robex Shareholders to vote their Robex Shares by depositing proxies is revised to 5:00 p.m. (Eastern Time) on December 29, 2025 (6:00 a.m. Australian Western Standard Time on December 30, 2025). The deadline for Robex CDI Holders to submit their CDI Voting Instruction Form is revised to 5:00 p.m. (Eastern Time) on December 28, 2025 (6:00 a.m. Australian Western Standard Time on December 29, 2025). NO FURTHER ACTION IS REQUIRED OF ROBEX SHAREHOLDERS WHO HAVE ALREADY VOTED THEIR ROBEX SHARES FOR THE ARRANGEMENT RESOLUTION IF THERE IS NO CHANGE TO THEIR VOTE. QUEBEC CITY, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Robex Resources Inc. (“Robex” or the “Corporation”) (TSX-V: RBX, ASX: RXR) announces that it has entered into an amending agreement (the “Amending Agreement”) with Predictive Discovery Limited (“Predictive”) (ASX: PDI) and 9548-5991 Québec Inc. (“Acquireco”) to amend the previously announced arrangement agreement dated October 5, 2025 (the “Arrangement Agreement”), pursuant to which Acquireco, a direct wholly-owned subsidiary of Predictive, will acquire all of the issued and outstanding common shares of Robex (“Robex Shares”) by way of a statutory plan of arrangement under Chapter XVI – Division II of the Business Corporations Act (Québec) (the “Arrangement” or the “Transaction”).

Under the terms of the Amending Agreement, holders of Robex Shares (“Robex Shareholders”) will now receive 7.862 fully paid ordinary shares in the capital of Predictive (“Predictive Shares”) for each Robex Share held (the “Amended Consideration”). Following completion of the Transaction, existing Predictive shareholders and former Robex Shareholders will own approximately 53.5% and 46.5%, respectively, of the combined company on a fully diluted in-the-money basis.

The terms of the Amending Agreement were agreed following receipt by Predictive of a competing superior proposal (“Competing Offer”) announced by Predictive on December 3, 2025 for all of the issued and outstanding Predictive Shares. In accordance with the terms of the Arrangement Agreement, the board of directors of Predictive subsequently determined that the Amending Agreement results in the Competing Offer ceasing to be a superior proposal under the Arrangement Agreement. A copy of the Amending Agreement has been filed on Robex’s SEDAR+ profile at www.sedarplus.ca.

Matthew Wilcox, Managing Director and CEO of Robex, commented:

“We want to sincerely thank the major shareholders for their unified view that strong potential value creation is only available in this transaction. The amended agreement provides both Robex and Predictive shareholders with attractive exposure to the merged group’s high-quality assets and positions them to benefit from a higher share price re-rate as we deliver our medium-term growth pipeline. This combination creates a stronger company with near-term cash flow from Kiniero and Bankan, project synergies, and access to a world-class mine building team with very recent construction experience in Guinea. Together, the combined company is well placed to deliver meaningful returns and build one of West Africa’s leading gold producers with the creation of a tier-1 gold mining hub in Guinea.”

Rationale for the Transaction:

Shareholder Support: Strong support from major shareholders for the amended transaction.Strategic Combination: The merger creates one of West Africa’s leading gold producers, combining two of the region’s largest, lowest-cost, and most advanced gold projects—Kiniero and Bankan—with projected production of 400koz+ annually by 2029 and combined resources of ~9.5Moz Au.Financial Flexibility: Cash flows from Kiniero and warrant proceeds from Robex provide funding capacity for Bankan’s development, reducing financing risk.
Project Synergies: Proximity of projects enables a tier-1 mining hub, optimising development, exploration, and workforce deployment.
Enhanced Market Profile: Greater scale and multi-asset nature position the combined company for potential inclusion in major indices (ASX 200, GDXJ), improving liquidity and investor appeal.
Experienced Leadership: A strengthened management team with proven in-country expertise and dual-listed company experience to drive effective execution.
Share Price Re-Rate: Potential for a higher relative share price re-rate of the merged group driven by increased scale, imminent gold production growth, multi-asset profile, and enhanced index inclusion opportunities. Second Fairness Opinions and Board Recommendation

The board of directors of the Corporation (the “Robex Board”) has received an updated opinion of Canaccord Genuity Corp. and the special committee of independent directors of the Robex Board (the “Robex Special Committee”) has received an updated opinion of Cormark Securities Inc. (together, the “Second Fairness Opinions”) to the effect that, as of the date of each such Second Fairness Opinion, and based upon and subject to the assumptions, limitations and qualifications set forth therein, the Amended Consideration to be received by Robex Shareholders is fair, from a financial point of view, to the Robex Shareholders.

Based on the unanimous recommendation of the Robex Special Committee, and after consultation with its outside financial and legal advisors, the Robex Board has unanimously determined that the Arrangement (as amended by the Amending Agreement) is in the best interests of Robex, and that the Amended Consideration to be received by Robex Shareholders pursuant to the Transaction is fair, from a financial point of view, to the Robex Shareholders, and that THE ROBEX BOARD UNANIMOUSLY RECOMMENDS TO ROBEX SHAREHOLDERS THAT THEY VOTE FOR THE ARRANGEMENT RESOLUTION (AS DEFINED BELOW) AT THE MEETING (AS DEFINED BELOW).

Amended Voting Agreements

Pursuant to the terms of the Amending Agreement, the Cohen Group, Eglinton Mining and all of the directors and certain members of senior management of Robex (each, a “Supporting Shareholder”), who in the aggregate own approximately 23.8% of the issued and outstanding Robex Shares, have each entered into amended and restated voting support agreements with Predictive, pursuant to which each Supporting Shareholder has consented to the Amended Consideration contemplated by the Amending Agreement and agreed to vote all of their Robex Shares in favour of approving the Arrangement Resolution at the Meeting.

Meeting Postponed to December 30, 2025

Robex’ special meeting of shareholders called to consider the Arrangement (the “Meeting”), previously scheduled for December 15, 2025 at 8:00 a.m. (Eastern Time) (9:00 p.m. Australian Western Standard Time), has been postponed to December 30, 2025 at 8:00 a.m. (Eastern Time) (9:00 p.m. Australian Western Standard Time) to allow Robex Shareholders with additional time to deposit proxies or voting instruction forms to vote FOR the Arrangement Resolution. The Meeting will be held virtually, via live video webcast at www.icastpro.ca/q04g09 (English) or www.icastpro.ca/hzwy58 (French). Robex Shareholders are required to pre-register for the Meeting at the foregoing links to be able to vote their Robex Shares in person at the Meeting and are urged to vote in advance of the Meeting by proxy.

At the Meeting, Robex Shareholders will be asked to consider and vote on a special resolution (the “Arrangement Resolution”) to approve the Arrangement. The Arrangement can only proceed if, among other conditions, the Arrangement Resolution receives the approval of not less than two-thirds (66⅔%) of the votes cast on the Arrangement Resolution by Robex Shareholders represented in person or by proxy at the Meeting.

Deadline to Deposit Proxies Revised to December 29, 2025

The form of proxy and voting instruction form (including CDI voting instruction forms) that were mailed to Robex Shareholders with the Management Information Circular in late November 2025 remain valid. Due to the postponement of the Meeting, Robex has extended the deadline to deposit proxies and CDI Voting Instruction Forms. The Robex Board urges Robex Shareholders to deposit their proxy form or voting instruction form and vote FOR the Arrangement Resolution ahead of the revised proxy deadline of 5:00 p.m. (Eastern Time) on December 29, 2025 (6:00 a.m. Australian Western Standard Time on December 30, 2025) (the “Revised Proxy Deadline”). Robex CDI Holders should submit their CDI Voting Instruction Form by to 5:00 p.m. (Eastern Time) on December 28, 2025 (6:00 a.m. Australian Western Standard Time on December 29, 2025) (the “Revised CDI VIF Deadline”).

No further action is required of Robex Shareholders who have already voted their Robex Shares FOR the Arrangement Resolution if there is no change to their vote.Robex Shareholders who have not already voted are encouraged to vote their Robex Shares FOR the Arrangement Resolution promptly, and in any case, prior to the Revised Proxy Deadline or Revised CDI VIF Deadline (as applicable), using the instructions provided in their proxy form or voting instruction form.Robex Shareholders who previously voted their Robex Shares AGAINST the Arrangement Resolution are encouraged to cast a new vote FOR the Arrangement Resolution promptly, and in any case, prior to the Revised Proxy Deadline or Revised CDI VIF Deadline (as applicable). The later-dated proxy or voting instructions supersedes any previous submission.In accordance with the terms of the Interim Order, the record date for the postponed Meeting remains November 3, 2025. Addendum to Information Circular

Pursuant to the terms of the Amending Agreement, Robex will issue a further press release and file an addendum (the “Addendum”) to the management information circular of the Corporation dated November 11, 2025 (the “Circular”) in respect of the Meeting, to provide Robex Shareholders with updated information in sufficient detail to permit them to form a reasoned judgment concerning the Arrangement Resolution. The Addendum will be supplemental to the information contained in the Circular and will be delivered to Robex Shareholders as well as made publicly available on SEDAR+, along with any other ancillary materials as required, in accordance with the terms of the Interim Order. The Circular will otherwise remain unchanged.

Shareholder Questions and Voting Assistance

Robex Shareholders who have questions about the information contained in this press release or require assistance with voting their shares, may contact Robex proxy solicitation agent and shareholder communications advisor:

Laurel Hill Advisory Group

Toll-Free: 1-877-452-7184 (for Shareholders in North America) or 1-800-861-409 (for CDI holders in Australia)
International: 1-416-304-0211 (for Shareholders outside North America)
By Email: [email protected]

Robex has engaged Canaccord Genuity as financial advisor, Peloton Legal Pty Ltd as Australian legal advisor, Osler, Hoskin & Harcourt LLP as Canadian legal advisor. Cormark Securities Inc. has been engaged as financial advisor to the Robex Special Committee.

This announcement was approved by the Managing Director.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Robex Resources Inc.
Matthew Wilcox, Managing Director and Chief Executive Officer
Alain William, Chief Financial Officer
Email: [email protected]

Investors and Media:
Michael Vaughan, Fivemark Partners
Phone: +61 422 602 720
Email: [email protected]

ABOUT ROBEX RESOURCES INC.
Robex Resources is a Canadian gold mining company listed on the TSX-V and ASX, and headquartered in Quebec, Canada. Robex’s material properties consist of the Nampala Project in Mali and the Kiniero Project in Guinea.

Not an Offer
No securities regulatory authority has either approved or disapproved of the contents of this news release. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The securities being offered have not been registered under the U.S. Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws.

Forward-looking Statements

This announcement contains certain forward-looking information and forward-looking statements within the meaning of applicable securities legislation (collectively “Forward-looking Information”). These include statements regarding future outlook and anticipated events, such as the consummation and timing of the Transaction and the satisfaction of the closing conditions under the Arrangement Agreement and the Amending Agreement; the timing of the Meeting and of the Revised Proxy Deadline; the filing and delivery of the Addendum, press release and any other ancillary materials; pro forma ownership of the combined company; and future plans, projections, objectives, estimates and forecasts and the timing related thereto. All statements, other than statements of historical fact, that address circumstances, events, activities or developments that could or may or will occur are Forward-looking Information. Forward-looking Information is generally identified by the use of words like “will”, “create”, “enhance”, “improve”, “potential”, “expect”, “upside”, “growth”, “estimate”, “anticipate” and similar expressions and phrases or statements that certain actions, events or results “may”, “could”, or “should”, or the negative or grammatical variations of such terms, are intended to identify Forward-looking Information. Although Robex believes that the expectations reflected in the Forward-looking Information are reasonable, undue reliance should not be placed on Forward- looking Information since no assurance can be provided that such expectations will prove to be correct. Forward-looking Information is based on information available at the time those statements are made and/or good faith belief of the officers and directors of Robex as of that time with respect to future events and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in or suggested by the Forward-looking Information. Forward-looking Information involves numerous risks and uncertainties. Such factors may include, but are not limited to, risks related to the closing of the Arrangement, changes in commodity prices, foreign exchange fluctuations and general economic conditions, increased costs and demand for production inputs, the speculative nature of exploration and project development, including the risks of obtaining necessary approvals, licenses and permits and diminishing quantities or grades of reserves, political and social risks (including, but not limited to, in Guinea, Ivory Coast, Mali and West Africa more broadly), changes to the legal and regulatory framework within which Robex operates or may in the future operate, environmental conditions including extreme weather conditions, recruitment and retention of personnel, industrial relations issues and litigation, as well as the risks identified in the section titled “Risk Factors” in Robex’s most recently filed Annual Information Form which is available on SEDAR+ at www.sedarplus.ca. Forward-looking Information is designed to help readers understand Robex' views as of that time with respect to future events and speak only as of the date they are made. Except as required by applicable law, Robex assumes no obligation to update or to publicly announce the results of any change to any Forward-looking Information contained or incorporated by reference herein to reflect actual results, future events or developments, changes in assumptions or changes in other factors affecting the Forward-looking Information. If Robex updates any Forward-looking Information, no inference should be drawn that Robex will make additional updates with respect to such or other Forward-looking Information. All Forward-Looking Information contained in this announcement is expressly qualified in its entirety by this cautionary statement.

JORC CODE AND CIM DEFINITION STANDARDS

The term “Ore Reserve” defined by the Australasian Code for Reporting of Exploration Results, Mineral Resources and Ore Reserves prepared by the Joint Ore Reserves Committee of the Australasian Institute of Mining and Metallurgy, Australian Institute of Geoscientists and Minerals Council of Australia (“JORC Code”) is equivalent to the term “Mineral Reserve” defined by the CIM Definition Standards for Mineral Resources & Mineral Reserves adopted by the Canadian Institute of Mining, Metallurgy and Petroleum May 19, 2014 (“CIM Definition Standards”). “Inferred Mineral Resources”, “Indicated Mineral Resources” and “Measured Mineral Resources” have the same meaning under both the JORC Code and CIM Definition Standards. “Proved Mineral Reserves” under the JORC Code has the same meaning as “Proven Mineral Reserves” under the CIM Definition Standards, and “Probable Mineral Reserves” under the JORC Code has the same meaning as “Probable Mineral Reserves” under the CIM Definition Standards. The JORC Code is an acceptable foreign code under NI 43-101.

Mineral Resources and Ore Reserve Estimates, and Production Targets

This announcement refers to PDI and Robex having combined Mineral Resource and Ore Reserve estimates of approximately 9.5Moz Au and approximately 4.5Moz Au respectively. Further information regarding the individual Mineral Resource and Ore Reserve estimates of each of PDI and Robex is set out below.

PDI

Mineral Resource and Ore Reserve Estimates

The Mineral Resource estimates for the NEB and BC projects were released to ASX on 7 August 2023 in an announcement by PDI titled “Bankan Mineral Resource Increases to 5.38Moz” and the Mineral Resource estimates in respect of the Fouwagbe and Sounsoun projects were released to the ASX on 23 April 2025 in an announcement by PDI titled “Maiden Argo Mineral Resource Estimate of 153koz”. The Ore Reserve estimate in respect of the Bankan Project was released to ASX on 25 June 2025 in an announcement by PDI titled “Bankan DFS Confirms Outstanding Project Economics”. PDI confirms it is not aware of any new information or data that materially affects the Mineral Resource or Ore Reserve estimates and all material assumptions and technical parameters underpinning the Mineral Resource and Ore Reserve estimates in the relevant market announcement continue to apply and have not materially changed, noting that PDI intends to appeal the Argo (and Bokoro) revocations announced on 28 May 2025 in accordance with the Mining Code, and that the Argo Inferred Mineral Resources account for just 2.8% of PDI’s overall Mineral Resource.

Production Targets

The Production Targets and forecast financial information in respect of the Bankan Project were released to the ASX on 25 June 2025 in an announcement by PDI titled “Bankan DFS Confirms Outstanding Project Economics”. PDI confirms that all the material assumptions underpinning the Production Targets and forecast financial information derived from the Production Targets in the previous announcement continue to apply and have not materially changed.

Robex

Mineral Resource and Ore Reserve Estimates

The Mineral Resource and Ore Reserve estimates in respect of Robex’s Kiniero Project were released to ASX on 22 August 2025 in an announcement by Robex titled “Amendment to Kiniero Gold Project Technical Report”, and in respect of the Nampala Project in an ASX announcement by Robex dated 6 May 2025 titled “Replacement Prospectus”. Robex confirms that it is not aware of any new information or data that materially affects the Mineral Resource and Ore Reserve estimates included in the relevant market announcement and all material assumptions and technical parameters underpinning the estimates in the announcement continue to apply and have not materially changed.

Production Targets

The production targets and forecast financial information in respect of Robex’s Kiniero Project was released to ASX on 22 August 2025 in an announcement by Robex titled “Amendment to Kiniero Gold Project Technical Report”, and in respect of the Nampala Project in an ASX announcement by Robex dated 6 May 2025 titled “Replacement Prospectus”. Robex confirms that all the material assumptions underpinning the production targets and forecast financial information derived from the production targets in the relevant market announcement continue to apply and have not materially changed.

National Instrument 43-101

All scientific and technical information in this presentation relating to Robex has been reviewed and approved by Mr. Jeames McKibben, a Chartered Professional Fellow of the Australian Institute of Mining and Metallurgy and a member of the Australian Institute of Geoscientists, and a “qualified person” as defined in NI 43-101.

Readers are referred to the technical report for the Nampala Project entitled “Independent Technical Report on the Nampala, Mininko, Gladie and Kamasso Permits and a Mineral Resource and Reserve Estimate of the Nampala Gold Mine, Mali, West Africa” effective September 30, 2024 (the “Nampala Technical Report), and the amended and restated technical report for the Kiniero Project entitled “Technical Report, Kiniero Gold Project, Guinea (Amended)” with an effective date of December 6, 2024, as amended and restated on June 12, 2025 (the “Kiniero Technical Report”), each of which has been prepared in accordance with NI 43-101 and is available on Robex’s profile on SEDAR+ at www.sedarplus.ca.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

PDI ORE RESERVE AND MINERAL RESOURCE STATEMENT

Bankan Ore Reserve Statement1,2

DepositMining MethodClassificationTonnage
(Mt)Gold Grade
(g/t Au)Contained
(Koz Au)NEB
Open PitProbable40.21.361,751UndergroundProbable7.93.951,002Total 48.11.782,753BC Open Pit
Open PitProbable3.51.78200Total 3.51.78200Total Open Pit  43.71.391,951Total Underground  7.93.951,002Total Bankan Project  51.61.782,953 Bankan Mineral Resource Statement3,4

DepositClassificationTonnage
(Mt)Gold Grade
(g/t Au)Contained
(Koz Au)NEB Open Pit
Indicated78.41.553,900Inferred3.10.9192Total81.41.533,993NEB UndergroundInferred6.84.07896NEB Total 88.31.724,888BC Open Pit
Indicated5.31.42244Inferred6.91.09243BC Total 12.21.24487NEB Area Total 100.51.665,376FouwagbeInferred2.21.68119SounsounInferred0.91.1934Argo Area Total 3.11.54153Total Bankan Project 103.61.665,528 ROBEX MINERAL RESERVE AND RESOURCE STATEMENT 

Kiniero Mineral Reserve and Resource Statement5,6

DepositTonnage
(Mt)Gold Grade
(g/t Au)Contained
(Moz Au)Probable   Jean4.21.530.20SGA5.11.520.25SGD3.41.340.14Sabali South7.40.890.21Sabali North and Central1.50.960.05Mansounia17.70.810.46Stockpiles6.30.480.10Total45.50.971.41Indicated   SGA12.11.460.57Jean4.71.690.26Sabali North and Central3.71.210.14Sabali South11.10.910.32West Balan3.01.450.14Banfara0.91.000.03Mansounia Central24.00.780.60Stockpiles11.60.370.14Total71.20.962.20Inferred   SGA10.61.430.49Jean2.21.470.1Sabali North and Central0.71.390.03Sabali South2.71.010.09West Balan2.01.270.08Banfara0.71.450.03Mansounia Central26.30.820.7Stockpiles0.21.310.01Total45.31.051.53 Nampala Mineral Reserve and Resource Statement7,8

Weathering TypeTonnage
(Mt)Gold Grade
(g/t Au)Contained
(Koz Au)Probable   Oxide3.30.9094.6Transition0.81.0626.4Total4.00.93121.0Indicated   Oxide5.90.84158.3Transition2.11.1376.0Fresh0.13.009.4Total8.00.94243.7Inferred   Oxide0.30.798.1Transition0.21.628.5Fresh0.012.530.4Total0.60.9517.0 ________________________________
1 Refer to PDI ASX release “Bankan DFS Confirms Outstanding Project Economics” dated 25 June 2025.
2 Reserve cut-off: Open Pit 0.38-0.48 g/t Au, Underground 2.0 g/t Au.
3 Resource cut-off: NEB Open Pit indicated & inferred 0.5 g/t Au, NEB Underground inferred 2.0 g/t Au, BC Open Pit indicated and inferred 0.4 g/t Au, Fouwagbe and Sounsoun inferred 0.5 g/t Au.
4 In relation to the Fouwagbe and Sounsoun deposits (Argo Permit), PDI intends to appeal the Argo and Bokoro revocations announced on 28 May 2025 in accordance with the Mining Code. Refer to PDI ASX release “Argo and Bokoro Exploration Permits Update” dated 28 May 2025.
5 Refer to Robex announcement titled “Amendment to Kiniero Gold Project Technical Report” dated 22 August 2025 and the Kiniero Technical Report.
6 Resource/reserve cut-off grade (Resource at US$2,200/oz, reserves at US$1,800/oz): SGA, Jean and Banfara: laterite 0.3 g/t Au, saprolite (oxide) 0.3 g/t Au, saprock (transition) 0.3 g/t Au, fresh 0.4 g/t Au; Sabali South: laterite 0.3 g/t Au, mottled zone/saprolite/lower saprolite (oxide) 0.3 g/t Au, saprock (transition) 0.5 g/t Au, fresh 0.6 g/t Au; Sabali North and Central: laterite 0.3 g/t Au, saprolite (oxide) 0.3 g/t Au, saprock (transition) 0.6 g/t Au, fresh 0.6 g/t Au; West Balan: laterite 0.3 g/t Au, saprolite (oxide) 0.3 g/t Au, saprock (transition) 0.3 g/t Au, fresh 0.5 g/t Au; Stockpiles reported as Mineral Resources have been limited to those dumps which exhibit an average grade >0.3 g/t Au for the entire stockpile assuming no selectivity.
7 Refer to Robex announcement titled “Replacement Prospectus” dated 6 May 2025 and the Nampala Technical Report.
8 Resource cut-off grade (at US$2,200/oz): Laterite 0.35 g/t Au, Oxide 0.35 g/t Au, Transition 0.43 g/t Au, Fresh 1.89 g/t Au; Reserve cut-off grade (at US$1,800/oz): 0.4 g/t Au (laterite, mottled zone, saprolite and transition).

A dip in membership renewal rates and concerns over operating costs are clouding the retailer's outlook after years of significant outperformance.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News:

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today released its 2026 financial calendar:

March 26, 2026: Publication of 2025 financial statements

May 13, 2026: Publication of revenue and cash position for 1Q2026

May 21, 2026: Annual General Shareholders Meeting

September 17, 2026: Publication of half year financial statements

November 5, 2026: Publication of revenue and cash position for 3Q2026

All financial reports are released before market opens CET.

All corporate information, such as the Company’s financial statements and corporate presentations, is available on the Investors section on the Company website.

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise on antibody-engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics.

Innate Pharma is advancing a portfolio of differentiated potential first and/or best-in-class assets, focused on areas of high unmet medical need, including IPH4502, a differentiated Nectin-4 ADC developed in solid tumors, lacutamab, an anti-KIR3DL2 antibody developed in cutaneous T cell lymphomas and peripheral T cell lymphomas, and monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer.

Innate Pharma has established collaborations with leading biopharmaceutical companies, including Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology. Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.

Information about Innate Pharma shares

Disclaimer on forward-looking information and risk factors

This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “may,” “might,” “potential,” “expect” “should,” “will,” or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s reliance on third parties to manufacture its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.

In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated November 25, 2025 to its short form base shelf prospectus dated October 31, 2025.
December 11, 2025 1:00 AM EST | Source: HIVE Digital Technologies Ltd.
San Antonio, Texas--(Newsfile Corp. - December 11, 2025) - HIVE Digital Technologies Ltd. (TSXV: HIVE) (NASDAQ: HIVE) (FSE: YO0) (BVC: HIVECO) (the "Company" or "HIVE"), a diversified multinational digital infrastructure company, is expanding its Latin American capital-markets presence with a new listing on the Colombian Stock Exchange—one of the region's deepest, broadest, and most institutionally connected exchanges. As part of the integrated Andean marketplace linking Colombia, Peru, and Chile, the exchange provides regional investors with enhanced access and cross-border liquidity.

By joining this platform, HIVE becomes the first Bitcoin-and-AI infrastructure company to list in Colombia, reinforcing its position as a major renewable-powered data center operator in Latin America and complementing its long-standing listings in Canada, Germany, and on Nasdaq.

This milestone strengthens HIVE's visibility among investors seeking exposure to sustainable high-performance computing, Bitcoin mining, and next-generation AI infrastructure across the Americas. It also aligns with Colombia's emergence as a regional technology hub and its growing participation in global AI governance frameworks.

The AI Industrial Revolution: How Bitcoin Miners Became the Early Pioneers

The world is entering a massive AI industrial revolution, with global demand for compute power far outpacing traditional data-center capacity. Industrial AI requires enormous energy throughput, advanced cooling, and highly scalable digital infrastructure—conditions that few industries were prepared to meet.

Bitcoin miners were among the first to solve these problems.

Long before AI hyperscalers began competing for power and GPUs, Bitcoin miners built:

large-scale compute clusterson surplus or stranded energywith high uptime requirementsacross remote and renewable energy marketsThis early pioneering work demonstrated that renewable, low-cost, underutilized energy could support mission-critical digital infrastructure at industrial scale. That foundation is now enabling the rise of Tier III+ HPC data centers stacked with GPU clusters, the new backbone of global AI computing.

HIVE was among the first to recognize this convergence—and is now executing one of the industry's clearest transitions from Tier I Bitcoin mining to Tier III AI and HPC cloud infrastructure.

Tiered Data Center Growth Strategy: From Tier I Surplus Energy to Tier III AI Compute

Foundational Tier I Buildout in Paraguay: HIVE has developed large-scale Tier I data centers in Paraguay powered entirely by hydroelectricity. These facilities support more than 25 Exahash per Second ("EH/s") of Bitcoin mining capacity, generating stable, recurring cash flow. Bitcoin miners like HIVE proved early on that large compute clusters could monetize stranded and surplus energy, paving the way for today's AI-driven data-center expansion.Upgrading to Advanced Tier III+ HPC: Building on this foundation, HIVE is converting key locations—including operations in Sweden and Canada—from Bitcoin-only Tier I sites into Tier III+ liquid-cooled HPC data centers. These facilities can host next-generation GPUs and hyperscale AI workloads, materially expanding HIVE's addressable market and accelerating time to revenue from enterprise AI and HPC cloud customers.Scaling GPU Capacity Across Renewable Power: HIVE's long-term roadmap includes deploying over 36,000 GPUs dedicated to AI and HPC cloud services. Each expansion phase is engineered around renewable, surplus, or stranded energy sources to maximize sustainability, resilience, and low-cost performance for compute-intensive applications.Multinational Operations and Latin America Expansion

HIVE now operates across nine time zones and five languages, with teams and infrastructure spanning Canada, Sweden and Paraguay. This global footprint strengthens regulatory agility, operational resilience, and local market development.

Paraguay as the Regional Blueprint

HIVE's Paraguay expansion—scaling toward 400 MW of renewable capacity—serves as its blueprint for community-focused digital infrastructure. The initiative includes local hiring, educational partnerships, and green-energy programs that support economic development and digital skills across the region.

A Strategic Inflection Point for Andean Investors

The Bogotá listing marks a strategic inflection point, opening a new, efficient capital-markets channel for investors across the interconnected Andean exchanges of Colombia, Peru, and Chile. It reinforces HIVE's long-term commitment to building responsible, sustainable digital infrastructure in Latin America at a time when the region is expanding its technology footprint and deepening its role in global AI transformation.

Revenue Momentum and Strategic Positioning

HIVE recently reported record quarterly revenue of $87.3 million, representing approximately 285% year-over-year growth, and gross operating margin of $42.4 million (49%), driven by strong Bitcoin production and rapidly rising demand for the company's BUZZ HPC cloud platform.

HIVE is executing a dual-engine strategy:

High-efficiency Bitcoin mining provides recurring cash flow.Cash flow is reinvested into Tier III+ AI-ready data center buildouts, powering long-cycle HPC and AI infrastructure growth.This flywheel positions HIVE to benefit from both Bitcoin's global adoption and the growth of industrial AI computing.

A New Convergence: Bitcoin Mining Meets Industrial AI

HIVE's evolution from Tier I mining assets to advanced Tier III AI data centers reflects a global convergence between digital-asset computation and industrial artificial intelligence. Bitcoin miners were among the first to demonstrate that massive, energy-intensive compute clusters could thrive on renewable, surplus, or stranded energy. Today, that expertise is driving the rise of GPU-dense HPC centers, enabling scientific computing, enterprise AI, and hyperscale cloud workloads.

As the AI super-cycle accelerates, HIVE is positioning itself at this intersection—bridging renewable energy, high-performance computing, and next-generation digital services. With its new listing on the Colombian Stock Exchange, HIVE now provides Latin American investors direct access to this transformation and to the industrial AI revolution reshaping global computing.

About HIVE Digital Technologies Ltd.

Founded in 2017, HIVE Digital Technologies Ltd. is the first publicly listed company to mine digital assets powered exclusively by green energy. Today, HIVE builds and operates next-generation blockchain and AI data centers across Canada, Sweden, and Paraguay, serving both Bitcoin and high-performance computing (HPC) clients. HIVE's twin-turbo engine infrastructure—driven by Bitcoin mining and NVIDIA GPU-accelerated AI computing—delivers scalable, environmentally responsible solutions for the digital economy.

For more information, visit hivedigitaltech.com, or connect with us on:

X: https://x.com/HIVEDigitalTech
YouTube: https://www.youtube.com/@HIVEDigitalTech
Instagram: https://www.instagram.com/hivedigitaltechnologies/
LinkedIn: https://linkedin.com/company/hiveblockchain

On Behalf of HIVE Digital Technologies Ltd.

"Frank Holmes"
Executive Chairman

For further information, please contact:
Nathan Fast, Director of Marketing and Branding
Frank Holmes, Executive Chairman
Aydin Kilic, President & CEO
Tel: (604) 664-1078

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277531

With this approval, Roche’s automated mass spectrometry platform now offers the industry’s broadest in vitro diagnostic menu with 39 tests, including tests for therapeutic drug monitoring for immunosuppressants and antibiotics, as well as steroid hormones and vitamin D metabolites.The comprehensive menu brings the sensitivity and specificity of gold-standard testing into routine labs for a wide range of the most frequently tested targets.The fully automated solution replaces labour-intensive manual workflows, reducing turnaround times and supporting faster, standardised, high-quality care. Basel, 11 December 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has secured CE Mark approval for its mass spectrometry reagent pack for antibiotics drug monitoring. This establishes Roche's in-vitro diagnostics (IVD) menu as the broadest available for any automated mass spectrometry platform, including already 39 of the most frequently tested targets.

“When patients get results sooner, we increase the likelihood that they will get the right treatment,” said Matt Sause, CEO of Roche Diagnostics. “With a comprehensive menu for automated mass spectrometry, we are giving clinicians and laboratories the tools to make faster, more precise diagnoses, reducing the time from sample to result. This approach also allows clinicians to better monitor the effectiveness of drug therapies and to optimise antibiotic use, a vital step in combating the major global healthcare challenge of antimicrobial resistance."

The cobas® Mass Spec solution Ionify® reagent portfolio includes tests for therapeutic drug monitoring for immunosuppressants and antibiotics, along with steroid hormones and vitamin D metabolites. These tests will enable laboratories to transition from labour-intensive and manual operation to a fully automated, standardised, easy to use solution.1-3 Roche remains committed to expanding this menu with additional assays in the coming years, including the first panel in drugs of abuse testing and further expanding the menu of therapeutic drug monitoring parameters.

The cobas Mass Spec solution is currently available in selected markets accepting the CE mark, as well as other markets including the United Kingdom, Canada and Japan. In parallel, Roche achieved "moderate complexity" categorisation under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) of the first analyte in the US. As the first mass spectrometry assay to receive this designation, it marks a significant step toward broadening clinical utility across routine laboratories by eliminating the need for specialists to run the assay.  Roche is continuously working with regulatory authorities around the world to further expand system and assay availability.

About the cobas Mass Spec solution
The high specificity, sensitivity and accuracy of mass spectrometry is considered the diagnostic ‘gold standard’ for various clinical situations, for example, measurements of steroid hormones in endocrinology, vitamin D testing, the monitoring of immunosuppressants and therapeutic drugs. The cobas Mass Spec solution combines the unmatched sensitivity and specificity of mass spectrometry with a fully automated, integrated, and standardised workflow, making this traditionally complex analytical method accessible to routine laboratories.

As part of the trusted cobas ecosystem, the cobas Mass Spec solution can integrate seamlessly with Roche’s clinical chemistry, immunochemistry, and laboratory IT systems, enabling laboratories to fully streamline workflows.

In July 2025, the cobas Mass Spec solution was awarded the Best New Clinical Diagnostics Instrumentation of 2024 in the Scientists' Choice Awards® 2025.  The Awards were first introduced in 2007 by SelectScience, with nominations collected and assessed by their editors and the most popular nominations put to vote among their readership of scientists.

For more information about the cobas Mass Spec, please visit diagnostics.roche.com/MassSpec

About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] Grebe SK, Singh RJ. LC-MS/MS in the Clinical Laboratory - Where to From Here? Clin Biochem Rev. 2011;32(1):5-31.
[2] Hristova J & Svinarov D. Enhancing precision medicine through clinical mass spectrometry platform. Biotechnology & Biotechnological Equipment. 2022;36(1):107-117.
[3] Ketha SS, Singh RJ, Ketha H. Role of Mass Spectrometry in Clinical Endocrinology. Endocrinol Metab Clin North Am. 2017;46(3):593-613.

Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: [email protected]

Hans Trees, PhD
Phone: +41 79 407 72 58Sileia Urech
Phone: +41 79 935 81 48Nathalie Altermatt
Phone: +41 79 771 05 25Lorena Corfas
Phone: +41 79 568 24 95Simon Goldsborough
Phone: +44 797 32 72 915Karsten Kleine
Phone: +41 79 461 86 83Kirti Pandey
Phone: +49 172 6367262Yvette Petillon
Phone: +41 79 961 92 50Dr Rebekka Schnell
Phone: +41 79 205 27 03  Roche Investor Relations

Dr Bruno Eschli
Phone: +41 61 68-75284
e-mail: [email protected] Sabine Borngräber
Phone: +41 61 68-88027
e-mail: [email protected] Birgit Masjost
Phone: +41 61 68-84814
e-mail: [email protected]  Investor Relations North America

Loren Kalm
Phone: +1 650 225 3217
e-mail: [email protected] 

Media Investor Release Mass Spec iPacks English

-

SINGAPORE--(BUSINESS WIRE)--With reference to the press release dated 2 December 2025 by BW LPG Limited (“BW LPG” or the “Company”, OSE ticker code: “BWLPG.OL”, NYSE ticker code “BWLP”) on key information relating to the cash dividend for Q3 2025, the shares of the Company will be traded ex-dividend on the Oslo Stock Exchange from today and from 12 December 2025 on the New York Stock Exchange.

About BW LPG

BW LPG is the world’s leading owner and operator of LPG vessels, owning and operating a fleet of more than 50 Very Large Gas Carriers (VLGCs) with a total carrying capacity of over 4 million CBM. With five decades of operating experience in LPG shipping, an in-house LPG trading division and investment in onshore LPG infrastructure, BW LPG offers trusted and reliable services to source and deliver LPG to customers. Delivering energy for a better world – more information about BW LPG can be found at https://www.bwlpg.com.

BW LPG is associated with BW Group, a leading global maritime company involved in shipping, floating infrastructure, deepwater oil & gas production, and new sustainable technologies. Founded in 1955 by Sir YK Pao, BW controls a fleet of over 450 vessels transporting oil, gas and dry commodities, with its 200 LNG and LPG ships constituting the largest gas fleet in the world. In the renewables space, the group has investments in solar, wind, batteries, and water treatment.

This information is subject to disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

More News From BW LPG Limited

Back to Newsroom

December 11, 2025 01:05 ET

 | Source:

Zealand Pharma

Press release – No. 19 / 2025

Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health

Zealand Pharma targets five launches, +10 clinical pipeline programs, and industry-leading cycle times from idea to clinic by 2030Catalyst-rich 2026 with multiple clinical readouts, including Phase 2 data with petrelintide in Q1 2026 and Phase 3 obesity data with survodutide throughout 2026New research site in Boston to combine our +25-year peptide heritage with AI-driven drug discovery, advanced automation, and next-generation molecule creation Copenhagen, Denmark, December 11, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today presents its strategy for redefining the near-term future of weight management and its vision to establish leadership in metabolic health at its Capital Markets Day in London. The Company will unveil its comprehensive strategy that combines strategic partnerships, accelerated drug development, and expanded research capabilities to build the world’s most valuable metabolic health pipeline.

Zealand Pharma will target five launches, a robust clinical pipeline of more than ten programs, and industry-leading cycle times from idea to clinic by 2030. By leveraging its unrivaled peptide expertise, strengthened organization, and expanded global research capabilities, alongside advanced computational methods and partnerships, Zealand Pharma will accelerate its drug discovery process and expand its molecule-making toolbox. This strategic approach, combined with five anticipated launches from the existing pipeline and the Company's robust financial foundation, will optimally position Zealand Pharma to achieve leadership in metabolic health.

“Today marks a pivotal moment for Zealand Pharma as we unveil our aim to build a generational biotech company that will fundamentally transform how we treat obesity and metabolic disease,” said Adam Steensberg, Chief Executive Officer of Zealand Pharma. “We are redefining weight management for a new era - moving beyond the Weight loss Olympics toward solutions that support the everyday needs, aspirations, and overall well-being of people living with overweight, obesity, and metabolic imbalance.

“Through Metabolic Frontier 2030 and beyond, we are committed to addressing some of the greatest healthcare challenges of our time. Our strategy is built to enable multiple waves of innovation in metabolic health - from our foundational amylin franchise to breakthrough approaches that will not only shatter the adherence ceiling observed with current medicines in obesity but deliver a world-class metabolic health pipeline.

“By establishing a cutting-edge Boston research site, we are putting advanced automation and AI to work alongside more than 25 years of unmatched peptide expertise to accelerate drug discovery and development, while expanding our molecule-making toolbox. This includes advancing oral small-molecule receptor agonists through our collaboration with OTR Therapeutics for validated targets within Zealand Pharma’s established areas of biological expertise. Together, these initiatives - with more to come - enable us to deliver on our strategy and continue advancing innovative solutions for people with overweight, obesity, and metabolic imbalance.”  

The event today will feature speakers from Zealand Pharma’s leadership team, alongside external experts and thought leaders in obesity and metabolism:

Zealand Pharma speakers

Adam Steensberg, Chief Executive OfficerHenriette Wennicke, Chief Financial OfficerDavid Kendall, Chief Medical OfficerEric Cox, Chief Commercial OfficerUtpal Singh, Chief Scientific Officer External experts

Dr. Carel Le Roux, MBChB, MSC, FRCP, FRCPath, PhD, Professor of Experimental Pathology at University College DublinJonathan Roth, PhD, Metabolic researcher and pioneer in amylin-leptin biologyLouis J. Aronne, MD, FACP, DABOM, Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medical College The Capital Markets Day will begin at 13:00 GMT and can be viewed via live webcast by registering here: https://zealand-pharma-capital-markets-day-dec-25.open-exchange.net/registration. A replay will be available on the company's website under Investors and Events & Presentations following the event.

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data‑driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health.

To date, more than ten Zealand Pharma‑invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization.

Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com.

Forward-looking statements
This press release contains “forward-looking statements”, as that term is defined in the Private Securities Litigation Reform Act of 1995 in the United States, as amended, even though no longer listed in the United States this is used as a definition to provide Zealand Pharma’s expectations or forecasts of future events regarding the research, development and commercialization of pharmaceutical products, the timing of the company’s pre-clinical and clinical trials and the reporting of data therefrom. These forward-looking statements may be identified by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “possible,” “potential,” “will,” “would” and other words and terms of similar meaning. You should not place undue reliance on these statements, or the scientific data presented. The reader is cautioned not to rely on these forward-looking statements. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect, and which include, but are not limited to, unexpected costs or delays in clinical trials and other development activities due to adverse safety events, patient recruitment or otherwise; unexpected concerns that may arise from additional data, analysis or results obtained during clinical trials; our ability to successfully market both new and existing products; changes in reimbursement rules and governmental laws and related interpretation thereof; government-mandated or market-driven price decreases for our products; introduction of competing products; production problems at third party manufacturers; dependency on third parties, for instance contract research or development organizations; unexpected growth in costs and expenses; our ability to affect the strategic reorganization of our businesses in the manner planned; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; regulatory authorities may require additional information or further studies, or may reject, fail to approve or may delay approval of our drug candidates or expansion of product labeling; failure to obtain regulatory approvals in other jurisdictions; exposure to product liability and other claims; interest rate and currency exchange rate fluctuations; unexpected contract breaches or terminations; inflationary pressures on the global economy; and political uncertainty. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. All such forward-looking statements speak only as of the date of this company announcement and are based on information available to Zealand Pharma as of the date of this announcement. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice.

Contacts
Adam Lange (Investors)
Vice President, Investor Relations
[email protected]

Neshat Ahmadi (Investors)
Investor Relations Manager
[email protected]

Rachel James-Owens (Media)
Vice President, Corporate Communications and Media Relations
Zealand Pharma
[email protected]

Amber Fennell, Jessica Hodgson, Sean Leous (Media)
ICR Healthcare
[email protected]
+44 (0) 7739 658 783  

Analyst’s Disclosure:I/we have a beneficial long position in the shares of AMZN either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Q3: 2025-12-10 Earnings SummaryEPS of -$0.92 beats by $0.02

 |

Revenue of

$307.34M

(-0.22% Y/Y)

beats by $1.75M

Oxford Industries, Inc. (OXM) Q3 2026 Earnings Call December 10, 2025 4:30 PM EST

Company Participants

Brian Smith
Thomas Chubb - Chairman, CEO & President
K. Grassmyer - Executive VP, CFO & COO

Conference Call Participants

Ashley Owens - KeyBanc Capital Markets Inc., Research Division
Janine Hoffman Stichter - BTIG, LLC, Research Division
Joseph Civello - Truist Securities, Inc., Research Division
Tracy Kogan - Citigroup Inc., Research Division
Mauricio Serna Vega - UBS Investment Bank, Research Division

Presentation

Operator

Greetings, and welcome to Oxford Industries Third Quarter Fiscal 2025 Earnings Conference Call. [Operator Instructions] Please note, this conference is being recorded.

I will now turn the conference over to Brian Smith from Oxford. Thank you, and you may begin.

Brian Smith

Thank you, and good afternoon. Before we begin, I would like to remind participants that certain statements made on today's call and in the Q&A session may constitute forward-looking statements within the meaning of the federal securities laws. Forward-looking statements are not guarantees, and actual results may differ materially from those expressed or implied in the forward-looking statements. Important factors that could cause actual results of operations or our financial condition to differ are discussed in our press release issued earlier today and in documents filed by us with the SEC including the risk factors contained in our Form 10-K. We undertake no duty to update any forward-looking statements.

During this call, we'll be discussing certain non-GAAP financial measures. You can find a reconciliation of non-GAAP to GAAP financial measures in our press release issued earlier today, which is posted under the Investor Relations tab of our website at oxfordinc.com.

And now I'd like to introduce today's call participants. With me today are Tom Chubb, Chairman and CEO; and Scott Grassmyer, CFO and COO. Thank you for your attention. And now I'd like to turn the call over

Recommended For You

FMC's stock crashed recently after the company slashed its dividend and released underwhelming earnings numbers.

When a stock plummets to multiyear lows, it's typically not a good sign for the business and its investors. It can signal that there's something deeply wrong with the business, its fundamentals, future, or all of the above.

If it's just a 52-week low, that may not be all that bad. But the longer back you have to go to find the last time the stock traded at its current levels, the worse the situation usually is. In some cases, however, the market can overreact and punish a stock excessively. In those circumstances, it could make for an attractive contrarian investment.

One stock that's been down big of late is FMC (FMC +1.87%). This year, it has lost more than 70% of its value. The sell-off has been so extreme that the stock is now trading at levels it hasn't been at since 2008 -- a whopping 17 years.

Is the stock really in a horrible position, or is this the case of an overreaction in the markets, meaning this could this be a good time to buy the stock for the long haul? Let's take a closer look.

Image source: Getty Images.

The company's financials haven't been looking good
FMC is a chemical manufacturing company that sells insecticides, herbicides, and other products that help farmers protect their crops. But the company has been struggling to grow its sales of late, and its bottom line has also been a big problem: FMC has incurred a net loss of $532 million over the trailing 12 months.

FMC Revenue (Quarterly) data by YCharts

The net loss in its most recent quarter looks worse than it really is, however. The company incurred restructuring charges and reported write-downs, which had significant impacts on its bottom line. The company is in the middle of restructuring its operations and is divesting its business in India, where it's facing tough market conditions due to high inventory levels.

For investors, this creates some added complexity in trying to determine just how strong the business will be amid all this noise and these financial adjustments. But even organically, the company says that for the third quarter, which ended on Sept. 30, its top line was down by 11%. While the divestment is playing a part in its weaker financials, the company is still facing some significant challenges beyond just India.

FMC recently slashed its dividend
It's one thing if a company has some bad results due to restructuring, but it's quite another when it makes a massive cut to its dividend, which is what FMC recently did. The company will now pay investors a quarterly dividend of $0.08, down from the previous $0.58. That equates to a massive 86% cut, which doesn't inspire much confidence in the business moving forward.

The company says the move was "part of a broader response to the challenges the company is facing, and to further prioritize debt reduction." As of the end of September, FMC's total debt was $4.5 billion. That's far higher than its cash and trade receivables, which total a combined $2.8 billion.

News of the underwhelming earnings report and dividend cut rattled the stock, which was trading at around $30 prior to the release of the numbers. Now, it's at less than half of that value. While FMC's current yield is still above average at 2.5% (the S&P 500 average payout is 1.2%), a big cut to the payout can crush any appeal in the stock from income-seeking investors, who often value reliability, consistency, and a strong track record when looking for quality dividend stocks.

Today's Change

(

1.87

%) $

0.25

Current Price

$

13.62

Is FMC a good contrarian stock to buy today?
FMC's stock is down big this year, and there is no reason to be terribly optimistic about a turnaround coming anytime soon. In its own forecast, the company references "cautious customer purchasing behavior," which suggests the business is bracing for continued challenges ahead.

This isn't much of a growth stock, and I wouldn't feel comfortable relying on the dividend, given the uncertainty ahead for the business. If FMC can't generate strong-enough results to get its debt under control, I wouldn't rule out the possibility of another cut to the dividend in the future.

With so many safer dividend stocks to choose from in the market, FMC isn't one I'd consider. Although it may look cheap, the stock simply isn't worth the risk.

Q1: 2025-12-10 Earnings SummaryEPS of -$5.20 beats by $0.00

 |

Revenue of

$271.03M

(4.13% Y/Y)

misses by $6.56M

Vail Resorts, Inc. (MTN) Q1 2026 Earnings Call December 10, 2025 5:00 PM EST

Company Participants

Connie Wang
Robert Katz - CEO & Executive Chairman
Angela Korch - Executive VP & CFO

Conference Call Participants

Shaun Kelley - BofA Securities, Research Division
Benjamin Chaiken - Mizuho Securities USA LLC, Research Division
David Katz - Jefferies LLC, Research Division
Arpine Kocharyan - UBS Investment Bank, Research Division
Charles Scholes - Truist Securities, Inc., Research Division
Chris Woronka - Deutsche Bank AG, Research Division
Jeffrey Stantial - Stifel, Nicolaus & Company, Incorporated, Research Division
Brandt Montour - Barclays Bank PLC, Research Division
Molly Baum - Morgan Stanley, Research Division

Presentation

Operator

Good afternoon, and welcome to the Vail Resorts Fiscal First Quarter 2026 Earnings Conference Call. Today's conference is being recorded. [Operator Instructions] I will now turn the call over to Connie Wang, Vice President of Investor Relations at Vail Resorts. You may begin.

Connie Wang

Thank you, operator. Good afternoon, and welcome to our fiscal 2026 first quarter earnings conference call. Joining me on the call are Rob Katz, our Chief Executive Officer; and Angela Korch, our Chief Financial Officer.

Before we begin, let me remind you that some information provided during this call may include forward-looking statements that are based on certain assumptions and are subject to a number of risks and uncertainties as described in our SEC filings, and actual future results may vary materially. Forward-looking statements in our press release issued this afternoon, along with our remarks on this call, are made as of today, December 10, 2025, and we undertake no duty to update them as actual events unfold.

Today's remarks also include certain non-GAAP financial measures. Reconciliations of these measures are provided in the tables included with our press release, which, along with our annual report on Form 10-Q, were filed this afternoon with the SEC and

Recommended For You

, /PRNewswire/ -- Live Nation will take over operations of Impact Arena, one of Thailand's most celebrated live entertainment venues, as it commits to upgrade the space and improve the concert experience for fans and artists.

Working alongside Impact's founding developer, Bangkok Land, Live Nation will introduce modern production infrastructure and enhanced hospitality. Upgrades include improved food and beverage options, premium seating experiences, and refreshed wayfinding, ticketing, and concessions. The venue will also feature curated design touches, from sophisticated exterior lighting to streamlined backstage amenities.

These improvements will not only enhance the fan experience but also enable faster turnaround times for artists and crews, creating more booking opportunities and supporting the local economy.

Impact Arena has long been at the heart of Thailand's live music scene, hosting some of the world's biggest stars. This partnership builds on that legacy by positioning the venue as a destination for all major touring acts while providing a platform for local talent—meeting the growing demand for live entertainment in the region.

Brands will also gain new opportunities to connect with fans through immersive onsite activations, with Disney On Ice, (G)I-DLE's 2026 World Tour, and Bowkylion already confirmed to perform at the venue in 2026.

Stephanie Bax, President, Venue Development for Live Nation Asia, said:
"Bangkok is one of Asia's most exciting cultural hubs, and Impact Arena has played a pivotal role in its live entertainment story. Together with Bangkok Land, we're breathing new life into this landmark venue and investing in the future of live music in Thailand, ensuring Impact Arena remains the must-play destination for both emerging local talent and global touring artists."

This partnership marks a significant step in Live Nation's global growth strategy, combining local expertise with international resources to reinforce Bangkok's position as a leading destination for live entertainment.

About Live Nation Entertainment
Live Nation Entertainment (NYSE: LYV) is the world's leading live entertainment company comprised of global market leaders: Ticketmaster, Live Nation Concerts, and Live Nation Sponsorship. For additional information, visit www.livenationentertainment.com.

SOURCE Live Nation Entertainment

Q3: 2025-12-10 Earnings SummaryEPS of $1.65 beats by $0.39

 |

Revenue of

$129.00M

(-6.00% Y/Y)

misses by $2.60M

Skillsoft Corp. (SKIL) Q3 2026 Earnings Call December 10, 2025 5:00 PM EST

Company Participants

Ronald Hovsepian - Executive Chairman & CEO
John Frederick - Chief Financial Officer

Conference Call Participants

Stephen Poe - Alpha IR Group LLC
Hoi-Fung Wong - Oppenheimer & Co. Inc., Research Division

Presentation

Operator

Thank you for standing by, and welcome to Skillsoft's Third Quarter Fiscal 2026 Results Conference Call. [Operator Instructions] Please note that today's call is being recorded, and a replay of the call and webcast will be available shortly after the call concludes for a period of 12 months.

I would now like to hand the conference over to your first speaker today, Stephen Poe, Investor Relations. Thank you. Please go ahead.

Stephen Poe
Alpha IR Group LLC

Thank you, operator. Good day, and thank you for joining us to discuss our results for the third quarter ended October 31, 2025. Before we jump in, I want to remind you that today's call will contain forward-looking statements about the company's business outlook and our expectations that constitute forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements concerning financial and business trends, our expected future business and financial performance, financial condition and market outlook.

These forward-looking statements and all statements that are not historical facts reflect management's current beliefs, expectations and assumptions and therefore, are subject to risks and uncertainties that could cause actual results to differ materially from the conclusions, forecasts, estimates or projections in the forward-looking statements made today. For a discussion of the material risks and other important factors that could affect our actual results, we refer you to our most recent Form 10-K and other documents that we file with the Securities and Exchange Commission. We assume no obligation to update any forward-looking statements or information, which speak as

Recommended For You

Analyst’s Disclosure:I/we have a beneficial long position in the shares of CRDO either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

December 10, 2025 11:34 PM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - December 10, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Primo Water Corporation (NYSE: PRMW) between June 17, 2024 and November 8, 2024, both dates inclusive, and/or (ii) purchasers of common stock of Primo Brands Corporation (NYSE: PRMB) between November 11, 2024 and November 6, 2025 (the "Class Period"), of the important January 12, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Primo Brands securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Primo Brands class action, go to https://rosenlegal.com/submit-form/?case_id=47890 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 12, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, Primo Brands formed following the November 8, 2024 merger between Primo Water and BlueTriton Brands, is a branded beverage company that offers beverage products across a variety of formats, channels, and price points. According to the lawsuit, throughout the Class Period, defendants misrepresented and failed to disclose key facts about the merger between Primo Water and BlueTriton Brands, including facts regarding the progress of the merger integration. Defendants issued a series of materially false and misleading statements that led investors to believe the merger would accelerate growth, generate transformative operational efficiencies, achieve meaningful synergies, and deliver strong financial results, and that the merger integration was proceeding "flawlessly." When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Primo Brands class action, go to https://rosenlegal.com/submit-form/?case_id=47890 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277615

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Inspire Medical Systems, Inc. (NYSE: INSP) between August 6, 2024 and August 4, 2025, both dates inclusive (the "Class Period"), of the important January 5, 2026 lead plaintiff deadline.

So what: If you purchased Inspire Medical common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Inspire Medical class action, go to https://rosenlegal.com/submit-form/?case_id=21452 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. If you wish to serve as lead plaintiff, you must move the Court no later than January 5, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, throughout the Class Period, defendants misrepresented and failed to disclose key facts about Inspire V, a sleep apnea device, including the actual market demand for the device and whether Inspire Medical had taken the steps necessary to launch it. Defendants issued a series of materially false and misleading statements that led investors to believe that demand for Inspire V was strong and that Inspire Medical had taken the necessary steps for a successful launch. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Inspire Medical class action, go to https://rosenlegal.com/submit-form/?case_id=21452 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

HomeStock IdeasLong IdeasIndustrial 

SummaryBird Construction is positioned to benefit from Canada's $115B infrastructure spending, supported by a record $10B project backlog.BDT:CA targets an 8% adjusted EBITDA margin and a 10% organic revenue CAGR by 2027, leveraging a favorable project mix and self-performance capabilities.Shares trade at a premium to historical averages (14.5x forward P/E, 12.2x EV/EBITDA), with further upside tied to earnings growth rather than multiple expansion.Dividend yield is 3.1% with a variable payout history, reflecting the cyclical nature of the construction industry and management's opportunistic capital returns.Alex_533/iStock via Getty Images

Investment Thesis I have been travelling across Canada in recent months. From coast to coast, I've noticed Bird Construction Inc. (BDT:CA) sites in downtown cores, university campuses, and industrial sites. Even as Canada enters a period of accelerated

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Quick Insights

Recommended For You

By

Aditi Bharade

You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.

David Ellison told WBD shareholders that it's "not too late" to switch teams from Netflix to Paramount.

PATRICK T. FALLON/AFP via Getty Images

2025-12-11T05:03:01.263Z

Paramount CEO David Ellison wrote a letter to WBD shareholders to win them over.
He urged WBD shareholders to tender their shares and switch teams from Paramount to Netflix.
He said WBD had not given equal treatment to Paramount during its sale process.

The media war between Warner Bros. Discovery, Netflix, and Paramount is raging on.

Paramount Skydance's CEO, David Ellison, sent a letter to WBD shareholders on Wednesday, urging them to tender their shares in support of Paramount's bid for WBD.

"It is not too late to realize the benefits of Paramount's proposal if you choose to act now and tender your shares," Ellison said in the letter.

Jon Stewart suggests Colbert's cancellation is tied to Paramount's Trump settlement

On Friday, Netflix announced that it would acquire WBD for $72 billion, after WBD rejected Paramount Skydance's offers and proceeded with a sale to Netflix. But on Monday, Paramount launched a hostile bid for WBD, for $30 per share.

In the letter, Ellison also slammed WBD's advisors for not giving equal weight to Paramount's offer, compared to Netflix's, and described the sales process as being "opaque."

"To suggest that we are not 'good for the money' (or might commit fraud to try to escape our obligations), as certain reports have speculated, is absurd," he said.

He said that WBD advisors "never picked up the phone or typed out a responsive text or email to raise any question or concern or to seek any clarification about either the trust or our equity commitment papers."

Ellison added that WBD did not grant Paramount a "single 'real time' negotiating session," and had "sprinted towards a deal with Netflix." He said WDB ignored texts from him and his advisors in which they said their $30-per-share offer was not their best and final one.

Representatives for WBD did not respond to a request for comment from Business Insider about Ellison's accusations in the letter.

After Paramount launched the hostile bid, Ellison pitched the deal to his own staff in an internal memo on Monday, as seen by Business Insider. He told his staff that the combination of Paramount and WBD would be a "powerful opportunity to strengthen both companies and the entertainment industry as a whole."

Business Insider previously reported that Ellison said at a Tuesday UBS event that he knew why WBD could not accept his latest offer.

"If they accept the offer exactly as it is today, right, then they're admitting breach of fiduciary duty, so I don't think they can just take that," Ellison said.

The bid is partially financed by the wealth funds from Saudi Arabia, Qatar, and Abu Dhabi.

The media war has not escaped the notice of President Donald Trump, who said he would be involved in the deal. He said on Sunday that the combined market share of Netflix and WBD "could be a problem."

Warner Bros.

Netflix

Read next

Ethereum price started a fresh increase above $3,350. ETH is now correcting gains from $3,450 and might decline further below $3,200.

Ethereum started a downside correction from the $3,450 zone.
The price is trading near $3,200 and the 100-hourly Simple Moving Average.
There was a break below a bullish trend line with support at $3,240 on the hourly chart of ETH/USD (data feed via Kraken).
The pair could continue to move down if it settles below the $3,200 zone.

Ethereum Price Declines Heavily
Ethereum price managed to stay above $3,200 and started a fresh increase, beating Bitcoin. ETH price gained strength for a move above the $3,320 and $3,350 resistance levels.

The bulls even pushed the price above $3,400. However, the bears were active below $3,450. A high was formed at $3,448 and the price is now correcting gains. There was a sharp decline below the 23.6% Fib retracement level of the upward wave from the $2,914 swing low to the $3,448 low.

Besides, there was a break below a bullish trend line with support at $3,240 on the hourly chart of ETH/USD. Ethereum price is now trading near $3,200 and the 100-hourly Simple Moving Average.

Source: ETHUSD on TradingView.com
If there is another upward move, the price could face resistance near the $3,250 level. The next key resistance is near the $3,300 level. The first major resistance is near the $3,320 level. A clear move above the $3,320 resistance might send the price toward the $3,400 resistance. An upside break above the $3,400 region might call for more gains in the coming days. In the stated case, Ether could rise toward the $3,450 resistance zone or even $3,500 in the near term.

More Losses In ETH?
If Ethereum fails to clear the $3,250 resistance, it could start a fresh decline. Initial support on the downside is near the $3,200 level. The first major support sits near the $3,180 zone and the 50% Fib retracement level of the upward wave from the $2,914 swing low to the $3,448 low.

A clear move below the $3,180 support might push the price toward the $3,150 support. Any more losses might send the price toward the $3,050 region. The next key support sits at $3,000.

Technical Indicators

Hourly MACD – The MACD for ETH/USD is gaining momentum in the bearish zone.

Hourly RSI – The RSI for ETH/USD is now below the 50 zone.

Major Support Level – $3,180

Major Resistance Level – $3,300

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

Strive, the bitcoin-focused issuer backed by Vivek Ramaswamy, launched an at-the-market plan to sell up to $500 million of its Variable Rate Series A Perpetual Preferred Stock.

Reports have disclosed the offering was filed on December 9, 2025 and that net proceeds may be used for general corporate purposes, including buying Bitcoin and Bitcoin-related products.

Strive Launches $500M Program
The public asset manager signed a sales agreement that names Cantor Fitzgerald, Barclays and Clear Street as placement agents for the program.

Based on reports, the ATM structure lets Strive sell SATA shares into the open market over time rather than in a single block. The prospectus supplement tied to the program makes clear how the offering fits into Strive’s capital toolbox.

Strive’s Announcement In Context
Strive has been steadily adding Bitcoin to its balance sheet this year. Reports show the firm bought about 1,567 BTC between October 28 and November 9 at an average price near $103,315 per coin, bringing total holdings to roughly 7,525 BTC as of early November.

These figures place Strive among the larger public corporate holders of Bitcoin and help explain why it is tapping preferred equity rather than other funding routes.

BTCUSD now trading at $91,835. Chart: TradingView
Bitcoin Holdings And Recent Buys
Based on reports, Strive’s stated goal is to increase Bitcoin per share over time. The company has framed preferred equity products like SATA as a way to fund future crypto buys while offering investors a different payout structure than common stock.

That mix — treasury Bitcoin plus income assets — is what Strive has pitched to shareholders in recent filings and investor updates.

Image: Nanalyze
Semler Deal And Earlier Purchase Plan
Reports have also tied Strive’s acquisition strategy to an earlier announcement to buy hundreds more coins as part of a corporate deal.

Reuters reported that in September Strive said it would buy 5,816 BTC for $675 million as part of its planned Semler acquisition, a move that would push combined holdings above 10,900 BTC if completed.

That disclosure underscores how the ATM program could fit into a broader plan to grow Bitcoin reserves.

Market Response
Stocks tied to Strive moved on the news. Some market pages recorded modest upticks in SATA and in Strive’s Class A common shares after the filing went public.

Investors and analysts will watch execution closely: an ATM sale can be gradual, and timing matters when buying a volatile asset like Bitcoin.

The preferred-stock route also has payout and conversion features that investors will weigh against dilution and cost of capital.

Featured image from Unsplash, chart from TradingView

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

Sign Up for Our Newsletter!
For updates and exclusive offers enter your email.

Christian, a journalist and editor with leadership roles in Philippine and Canadian media, is fueled by his love for writing and cryptocurrency. Off-screen, he's a cook and cinephile who's constantly intrigued by the size of the universe.

A noted Bitcoin adviser has warned that Shiba Inu faces an uphill climb unless it retakes a prior support band, a call that has stirred debate across crypto social channels.

According to posts by BingX Bitcoin adviser Nebraskan Gooner, the token must return above a horizontal region he marked between $0.000014 and $0.00001 to avoid a “dead” outlook.

Key Support Level Under Scrutiny
Gooner’s chart points to a multi-year zone that once acted as firm support. Reports show SHIB touched that band and later surged to about $0.000045 in early March 2024.

The importance of the area is highlighted by the token’s price action: it has spent much of Q4 2025 below that range, and at the time of reporting SHIB was trading around $0.000008618.

That places the coin roughly 33–38% below the $0.000013–$0.000014 region that many traders watch as critical.

$SHIB

Dead unless it reclaims red. pic.twitter.com/LOllFuyPYv

— Nebraskangooner (@Nebraskangooner) December 9, 2025

Technical Traders See Trouble Ahead
Breaking a long-held support level often flips buying interest into resistance, and that scenario is what traders fear here. Based on reports from market commentators, a failure to climb back into the red band would make upward moves harder and likely sap momentum.

Gooner used blunt language, saying “Dead unless it reclaims red” unless the token reclaims the zone. The phrase was repeated widely, feeding both bearish calls and pushback from supporters.

Community Response And Roadmap Calls
Across social threads, many users argued that SHIB is not unique; several altcoins appear stalled in the current phase. A number of holders said SHIB’s recovery chances may hinge on a wider altcoin rebound, sometimes called altcoin season.

SHIB market cap currently at $5.01 billion. Chart: TradingView
According to Zach Humphries, members of the Shiba Inu project must refocus every ecosystem initiative around SHIB, reposition the token to attract renewed retail interest, and publish a clear, actionable roadmap to restore earlier momentum.

Bitcoin’s Role In A Possible Comeback
Some analysts pointed to Bitcoin as the likely spark for any broad recovery, expecting the alpha coin to rebound toward $125,000 from around $90,000, while others have projected a new peak near $150,000 in 2026. If Bitcoin climbs above $100,000, traders say speculative flows could return and lift meme tokens including SHIB.

Price Snapshot And What Comes Next
Short-term price moves show SHIB up 0.95% in the past 24 hours but down 4.8% over the last week. Many market observers emphasize that a return into the highlighted $0.000014–$0.00001 area would improve technical odds for a rally.

At the same time, others warn that even with historical liquidity and a large community, reclaiming a broken support is often difficult and can take time. The coming weeks will likely test whether market-wide momentum or renewed project direction can change SHIB’s path.

Featured image from Unsplash, chart from TradingView

This biotech targeting rare genetic diseases reported a notable insider sale following a year of rapid share price gains.

Barry Ticho, Chief Medical Officer at Stoke Therapeutics (STOK +11.95%), executed an option exercise and open-market sale of 5,358 common shares for a total consideration of approximately $167,115 on Dec. 4 and Dec. 5, 2025, according to the SEC Form 4 filing.

Transaction summaryMetricValueShares sold (direct)5,358Transaction value~$167,115Post-transaction shares (direct)19,798Post-transaction value (direct ownership)~$611,164.3Transaction value based on SEC Form 4 weighted average purchase price ($31.19); post-transaction value based on Dec. 5, 2025 market close.

Key questionsHow does the transaction size compare to Mr. Ticho's historical selling activity?
The 5,358-share sale is smaller than Mr. Ticho's median historical sale of 7,194 shares, but it represents a much larger proportion of his remaining holdings (21.30% versus the long-term median of 6.84%), reflecting the marked decline in his available share base.What is the significance of the derivative context in this transaction?
This event involved exercising 10,000 stock options, of which 5,358 shares were immediately sold; this mechanism is commonly used to fund tax liabilities or monetize newly vested equity, and resulted in no change to indirect or trust-held shares.Did the market price at execution materially differ from recent trading levels?
Shares were sold at a weighted average of around $31.19, closely tracking the market close of $30.87 on Dec. 5, 2025, and the most recent price of $30.47 as of Dec. 9, 2025 — indicating little slippage or timing premium.Does this transaction signal a shift in selling cadence or intent?
The proportionally larger sale is a function of reduced direct holdings — not a change in disposition pattern; Mr. Ticho has consistently executed similar option-related sales throughout the past year as his share count has declined by over 86% during that period.Company overviewMetricValuePrice (as of market close Dec. 5, 2025)$31.19Market capitalization$1.74 billionRevenue (TTM)$205.63 million1-year price change121.44%* 1-year performance calculated using Dec. 5, 2025 as the reference date.

Company snapshotStoke Therapeutics develops antisense oligonucleotide (ASO) medicines targeting severe genetic diseases, with lead candidates STK-001 for Dravet syndrome (in Phase I/IIa trials) and STK-002 for autosomal dominant optic atrophy (preclinical).It generates revenue primarily through the development and potential commercialization of proprietary RNA-based therapeutics, as well as collaboration and license agreements with pharmaceutical partners.The company targets patients with rare, severe genetic neurodevelopmental and neurological disorders, focusing on unmet medical needs in the United States and select global markets.Stoke Therapeutics, Inc. operates as a clinical-stage biotechnology company specializing in RNA-based medicines for severe genetic diseases. The company leverages its proprietary platform to upregulate protein expression, aiming to address conditions with limited treatment options. Strategic collaborations and a focused pipeline provide Stoke with a differentiated position in the rare disease therapeutics landscape.

What this transaction means for investorsStoke's Chief Medical Officer Barry Ticho's Dec. 4 and Dec. 5 sales of stock is not necessarily a cause for alarm. He still held nearly 20,000 shares at the end of the transaction. Stoke Therapeutics stock has been on a tear in the latter half of 2025, reaching a 52-week high of $38.69 on Oct. 16, and remaining above $30 per share in December. Mr. Ticho was likely taking advantage of the stock price appreciation to cash in some shares.

The company's stock price is up thanks to favorable clinical trial data for its lead drug candidate, zorevunersen, a strategic collaboration with Biogen, and compelling financial results.

In the third quarter, Stoke Therapeutics reported $328.6 million in cash, cash equivalents, and marketable securities, and $183 million in year-to-date revenue. Management stated its financial position is anticipated to fund operations until 2028.

The company looks like it's on a solid business trajectory. Mr. Ticho's December stock sales don't signal a red flag, but rather, that he was taking advantage of price appreciation. So shareholders should not feel pressured to dump their holdings.

GlossaryOption exercise: When an individual uses their right to buy company shares at a set price through stock options.
Open-market sale: Selling shares directly on a public stock exchange, rather than through a private transaction.
SEC Form 4: A required filing that discloses insider trades by company officers, directors, or significant shareholders.
Derivative event: A transaction involving financial instruments whose value is based on underlying assets, such as stock options.
Weighted average price: The average price of shares sold, weighted by the number of shares at each price.
Direct holdings: Shares owned personally by an individual, not through trusts or other entities.
Indirect entities: Organizations or accounts, like trusts, through which an individual may hold shares.
Disposition: The act of selling or otherwise transferring ownership of an asset.
Vested equity: Shares or options that an employee has earned the right to own or sell, usually after meeting certain conditions.
Slippage: The difference between the expected price of a trade and the actual price received.
Cadence: The regular pattern or frequency of a repeated activity, such as insider share sales.
TTM: The 12-month period ending with the most recent quarterly report.